At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
|Articles|October 28, 2021
Pharmacy Clinical Pearl of the Day: Colon Cancer
Author(s)Saro Arakelians, PharmD
Chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).
Advertisement
Clinical Pearl of the Day: Colon Cancer
Colon cancer is a type of cancer that begins in the large intestine (colon).
Insight:
- Colon cancer typically affects older adults, though it can happen at any age.
- Symptoms may include change in bowel habits, diarrhea, constipation, rectal bleeding, persistent abdominal discomfort, weakness or fatigue, and unexplained weight loss.
- Risk factors include older age, African American race, history of colorectal cancer, inflammatory intestinal conditions, obesity, diabetes, smoking, alcohol use, and family history.
- Treatment includes polypectomy, mucosal resection, partial colectomy, lymph nodes removal, chemotherapy, radiation therapy, targeted drug therapy, immunotherapy, and palliative care.
- Some drugs used as chemotherapy for colorectal cancer include 5-fluorouracil (5-FU), capecitabine (Xeloda), irinotecan (Camptosar), oxaliplatin (Eloxatin), and trifluridine and tipiracil (Lonsurf).
Sources:
Advertisement
Related to this article
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar with it and with the potential risks.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
4
Survodutide Shows Cardiovascular Safety in SYNCHRONIZE-CVOT
5